All patients
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 Gender, female Gender, male LDH > ULN LDH ≤ULN metastasis (liver )
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
studies
Extensive stage SCLC (Es-SCLC) - maintenance (M), immune chekpoint inhibitors vs. all, meta-analysis of study results Outcome TE 95% CI n k I2 ROB Pub. bias deaths (OS)detailed results CheckMate 451 (N ; all population), 2019 0.84 [0.69; 1.02]
CheckMate 451 (NI ; all population), 2019 0.92 [0.75; 1.12]
0.88 [0.76 ; 1.01 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 0% 1,109 moderate not evaluable progression or deaths (PFS)detailed results CheckMate 451 (N ; all population), 2019 0.67 [0.56; 0.81]
CheckMate 451 (NI ; all population), 2019 0.72 [0.60; 0.87]
0.69 [0.61 ; 0.79 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 0% 1,109 moderate not evaluable objective responses (ORR)detailed results CheckMate 451 (N ; all population), 2019 2.93 [1.44; 5.95]
CheckMate 451 (NI ; all population), 2019 2.33 [1.11; 4.90]
2.63 [1.57 ; 4.39 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 0% 1,109 moderate not evaluable TRAE (any grade)detailed results CheckMate 451 (N ; all population), 2019 1.49 [1.06; 2.08]
CheckMate 451 (NI ; all population), 2019 4.23 [2.89; 6.20]
2.50 [0.90 ; 6.96 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 94% 1,109 moderate not evaluable TRAE (grade 3-4)detailed results CheckMate 451 (N ; all population), 2019 1.59 [0.90; 2.79]
CheckMate 451 (NI ; all population), 2019 12.44 [7.59; 20.41]
4.47 [0.59 ; 33.57 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 97% 1,109 moderate not evaluable TRAE leading to death (grade 5)detailed results CheckMate 451 (N ; all population), 2019 0.98 [0.06; 15.78]
CheckMate 451 (NI ; all population), 2019 7.05 [0.86; 57.70]
3.27 [0.50 ; 21.53 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 19% 1,109 moderate not evaluable TRAE leading to discontinuation (any grade)detailed results Out of scale CheckMate 451 (N ; all population), 2019 20.14 [4.80; 84.52]
CheckMate 451 (NI ; all population), 2019 60.82 [14.79; 250.13]
35.24 [11.93 ; 104.09 ] CheckMate 451 (N ; all population), 2019, CheckMate 451 (NI ; all population), 2019 2 14% 1,109 moderate not evaluable 0.5 20.0 1.0 relative treatment effect www.metaEvidence.org 2024-10-05 19:00 +02:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 194
- treatments: 204,504,850,329,558,579,549,868,502,741,556,812,813,367,851,361,602,1070,671,865,744,696,1083,1281,1282,1283,1082,866,852,417,603,1051,876,853,1018,661,673,1049,1440,1561,854,374,953,672,1080,1560,1073,862,1562,1565,855,360,719,721,720,842,642,674,1085,863,503,847,982,359,575,577,576,869,1081,981,875,505,952,1021,1079,767,1071,1074,873,561,644,1251,1044,724,874,1043,1041,1042,940,1258,1563,746,745,856,634,861,416,864,769,980,369,743